JP7421232B2 - フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体 - Google Patents

フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体 Download PDF

Info

Publication number
JP7421232B2
JP7421232B2 JP2021544519A JP2021544519A JP7421232B2 JP 7421232 B2 JP7421232 B2 JP 7421232B2 JP 2021544519 A JP2021544519 A JP 2021544519A JP 2021544519 A JP2021544519 A JP 2021544519A JP 7421232 B2 JP7421232 B2 JP 7421232B2
Authority
JP
Japan
Prior art keywords
bond
group
formula
amino acid
hydrophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021544519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518598A (ja
JP2022518598A5 (https=
Inventor
ディ・カルロ，ダニエル
ウェスター，ハンス－ユルゲン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Original Assignee
Technische Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen filed Critical Technische Universitaet Muenchen
Publication of JP2022518598A publication Critical patent/JP2022518598A/ja
Publication of JP2022518598A5 publication Critical patent/JP2022518598A5/ja
Application granted granted Critical
Publication of JP7421232B2 publication Critical patent/JP7421232B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021544519A 2019-01-30 2020-01-29 フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体 Active JP7421232B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19154636 2019-01-30
EP19154636.5 2019-01-30
PCT/EP2020/052159 WO2020157128A1 (en) 2019-01-30 2020-01-29 Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof

Publications (3)

Publication Number Publication Date
JP2022518598A JP2022518598A (ja) 2022-03-15
JP2022518598A5 JP2022518598A5 (https=) 2022-12-23
JP7421232B2 true JP7421232B2 (ja) 2024-01-24

Family

ID=65268875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544519A Active JP7421232B2 (ja) 2019-01-30 2020-01-29 フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体

Country Status (7)

Country Link
US (1) US12576169B2 (https=)
EP (1) EP3917581A1 (https=)
JP (1) JP7421232B2 (https=)
CN (1) CN113677375B (https=)
AU (1) AU2020213892B2 (https=)
BR (1) BR112021012110A2 (https=)
WO (1) WO2020157128A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
WO2022018264A1 (en) * 2020-07-23 2022-01-27 Technische Universität München Silicon-containing ligand compounds
JP2024544153A (ja) 2021-11-16 2024-11-28 テクニシェ ユニバーシタット ミュンヘン 溶解した［１８ｆ］フッ化物を含む組成物の調製方法およびその方法によって得ることができる組成物
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536790A (ja) 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
US20170246327A1 (en) 2014-10-20 2017-08-31 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP2018521956A (ja) 2015-05-26 2018-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 分子および生体分子の１８ｆ標識化に有用な新規な複素芳香環フッ化ケイ素アクセプタおよびその調製方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
HUE070098T2 (hu) 2017-07-28 2025-05-28 Univ Muenchen Tech Kettõs módusú radioaktív jelzõ és terapeutikumok

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536790A (ja) 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
US20170246327A1 (en) 2014-10-20 2017-08-31 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP2018521956A (ja) 2015-05-26 2018-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 分子および生体分子の１８ｆ標識化に有用な新規な複素芳香環フッ化ケイ素アクセプタおよびその調製方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Dialer, L.O. et al.，Studies toward the development of new silicon-containing building blocks for the direct 18F-labeling of peptides，Journal of Medicinal Chemistry，2013年08月30日，Vol. 56，pp. 7552-7563
Lindner, S. et al.，Synthesis and in vitro and in vivo evaluation of SiFA-tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography，Bioconjugate Chemistry，2014年03月25日，Vol. 25，pp. 738-749
Litau, S. et al.，Next generation of SiFAlin-based TATE derivatives for PET imaging of SSTR-positive tumors: influence of molecular design on in vitro SSTR binding and in vivo pharmacokinetics，Bioconjugate Chemistry，2015年09月30日，Vol. 26，pp. 2350-2359

Also Published As

Publication number Publication date
JP2022518598A (ja) 2022-03-15
EP3917581A1 (en) 2021-12-08
CN113677375B (zh) 2024-07-23
WO2020157128A1 (en) 2020-08-06
CA3123738A1 (en) 2020-08-06
AU2020213892B2 (en) 2025-04-10
AU2020213892A1 (en) 2021-07-22
BR112021012110A2 (pt) 2021-09-08
US20220096669A1 (en) 2022-03-31
CN113677375A (zh) 2021-11-19
US12576169B2 (en) 2026-03-17

Similar Documents

Publication Publication Date Title
JP7572080B2 (ja) 画像化および内部放射線療法のためのｐｓｍａリガンド
RU2523531C2 (ru) Конъюгаты антагониста пептида аналога бомбезина
CN101151054B (zh) 放射性氟化肽
JP7421232B2 (ja) フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体
US12156920B2 (en) Double-labeled probe for molecular imaging and use thereof
EP3209336A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2017054907A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
CN116981486A (zh) 双模式放射性示踪剂和治疗剂
CN117042812A (zh) 用于诊断和治疗用途的cxcr4-配体及其前体
EP3494999A1 (en) Psma ligands for imaging and endoradiotherapy
CA3123738C (en) Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof
RU2807076C2 (ru) Лиганды PSMA для визуализации и эндорадиотерапии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240104

R150 Certificate of patent or registration of utility model

Ref document number: 7421232

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150